GlassScriptPhysician profile
Sonia J Lahoti
NPI 1922033869
$3,725.23
in general payments reported to CMS, 2019-2025
26 companies · $539 in 2025
The $539 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $286 · 2021: $1,185 · 2022: $565 · 2023: $512 · 2024: $443 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,476 · Education: $17.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,476.07 |
| Education | $17.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $684.25 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $404.76 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $339.00 | 2021-2024 | Lifevest |
| Abbvie INC. | $277.09 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $275.82 | 2019-2025 | |
| Amgen INC. | $258.84 | 2019-2023 | Repatha |
| Impulse Dynamics (USA) INC. | $208.58 | 2023 | Optimizer |
| Inari Medical, INC. | $195.74 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abbott Laboratories | $188.75 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $168.42 | 2019-2021 | |
| Endotronix, INC. | $146.57 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| E.R. Squibb & Sons, L.L.C. | $81.18 | 2020-2025 | Eliquis |
| Novo Nordisk INC | $78.45 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Heartflow, INC. | $66.94 | 2024-2025 | |
| Pfizer INC. | $64.92 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $41.31 | 2021 | |
| Lilly USA, LLC | $40.92 | 2021-2025 | Zepbound |
| Boston Scientific Corporation | $35.74 | 2020-2021 | |
| Edwards Lifesciences Corporation | $30.19 | 2023 | Sapien 3 Ultra Resilia |
| Cvrx, INC. | $27.11 | 2023 | Barostim Neo System |
| Itamar Medical INC | $25.52 | 2024 | Watchpatone |
| Bardy Diagnostics, INC. | $24.00 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $17.57 | 2023 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $17.22 | 2025 | Rexulti |
| Regeneron Healthcare Solutions, INC. | $13.42 | 2019 | |
| Allergan, INC. | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Lahoti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.